Although β3AR agonists are clinically used only for the treatment of overactive bladder syndrome (Sacco and Bientinesi, 2012; Igawa and Michel, 2013), β3AR has been also postulated as a putative target for the treatment of other diseases such as heart failure (Cannavo and Koch, 2017). This evidence concerns the gene ADRB3 and heart failure.